Session: Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy
Disclosures: Marson: Arsenal Bioscience: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Other: Compensated co-founder; Spotlight Therapeutics: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Other: Compensated co-founder; Survey Genomics: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Other: Co-founder; NewLimit: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; PACT Pharma: Current equity holder in private company, Other: Speaking and/or advising fees; 23andMe: Other: Speaking and/or advising fees; June Therapeutics: Other: Speaking and/or advising fees; Research funding; Amgen: Other: Speaking and/or advising fees; Offline Ventures: Other: Investor, informal advisor; EPIQ: Other: Client; Gilead: Research Funding; Anthem: Research Funding; Tenaya Therapeutics: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Lighthouse Discovery Ltd: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees.
See more of: Scientific Program